<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Hyperthermic intraperitoneal chemoperfusion (HIPEC) with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> is increasingly used in patients with <z:e sem="disease" ids="C0205699" disease_type="Neoplastic Process" abbrv="">carcinomatosis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>For reasons of chemical stability, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> can only be administered in a <z:chebi fb="10" ids="4167">dextrose</z:chebi> (D5%) solution, and this causes peroperative <z:chebi fb="105" ids="17234">glucose</z:chebi> and electrolyte shifts </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we examined the influence of perfusion temperature on <z:chebi fb="105" ids="17234">glucose</z:chebi> and electrolyte transport, metabolic shifts, and surgical morbidity </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patients with <z:e sem="disease" ids="C0205699" disease_type="Neoplastic Process" abbrv="">carcinomatosis</z:e> underwent cytoreduction and HIPEC using <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (460 mg/m(2) in D5%, open abdomen) during 30 min at 39°-41 °C </plain></SENT>
<SENT sid="4" pm="."><plain>Intraperitoneal (IP) temperature was measured at three locations using thermocouple probes </plain></SENT>
<SENT sid="5" pm="."><plain>The area under the temperature versus time curve (AUCt) was calculated using the trapezoid rule </plain></SENT>
<SENT sid="6" pm="."><plain>The influence of perfusion temperature on surgical outcome was assessed using linear regression models and the Mann Whitney U test where appropriate </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: From July 2005 until March 2011, 145 procedures were performed in 139 patients with a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (70%), <z:mpath ids='MPATH_303'>pseudomyxoma peritonei</z:mpath> (11%), <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> (10%), or miscellaneous peritoneal <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (9%) </plain></SENT>
<SENT sid="8" pm="."><plain>Postoperative mortality and major morbidity were 1.4% and 26%, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>Higher perfusion temperature was related to more pronounced changes in serum <z:chebi fb="105" ids="17234">glucose</z:chebi> (P = 0.058), <z:chebi fb="199" ids="26708">sodium</z:chebi> (P = 0.017), and <z:chebi fb="4" ids="24996">lactate</z:chebi> (P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>The median duration of nasogastric drainage was 5 days, and this was unrelated to perfusion temperature (P = 0.76) </plain></SENT>
<SENT sid="11" pm="."><plain>The GI <z:mpath ids='MPATH_70'>fistula</z:mpath> rate and reoperation rate were 12.4% and 16.5% respectively; neither was related to perfusion temperature </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: In patients undergoing HIPEC with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, perfusion temperature exacerbates peroperative metabolic shifts but does not affect surgical outcome </plain></SENT>
</text></document>